Relevant Experience
Eric Greenberg has more than 30 years of experience representing clients in food and drug law matters, and he has been recognized worldwide for his capable handling of these often complex matters. Our firm’s dedicated focus on food and drug law puts us in a uniquely strong position to address your needs.
Meet Eric
Effective Representation
We regularly advise clients on regulatory compliance with requirements of the Food and Drug Administration (FDA) and state and local laws and represent them in actions related to alleged violations. We take the time to gain a complete understanding of our clients’ concerns and develop customized solutions designed specifically to address them.
View Topics
GRAS Goes to Congress
By Eric F. Greenberg, Attorney-at-law
Remember that whole business involving NGOs and other folks objecting to the legal system that allows companies to self-determine that their uses of substances are Generally Recognized As Safe (“GRAS”)? And remember how some groups had gone to court to get the system declared unlawful, but late last year the court ruled against them? Well, there’s a new chapter to this story. Now, some members of Congress have proposed a bill that would make changes to the law to address those very same objections.
The GRAS pathway to clearance of the use of substances in packaging and in food is crucially important, and this proposed law has the potential to make enormous changes in various legal obligations. For that reason, packagers should keep a close eye on this latest chapter in the ongoing debate over the policy issues surrounding the GRAS system.
In my view, addressing the complaints we’ve heard for years about the GRAS program required changes in the law, so at least the objectors are in the correct forum. There’s been so much criticism of the Food and Drug Administration lately, what with its slow reaction to the infant formula contamination problem, on top of its handling of issues relating to heavy metals in baby food and various complaints about its handling of COVID and other drug approvals, for some examples. But when it comes to the GRAS program, it’s always seemed that most of the objectors’ objections were better directed at Congress than at FDA.
You have questions, We have answers. Request a consult.
Learn More About Our Legal Services
Our firm is a proud member of the International Network of Boutique Law Firms, a select organization with member law firms throughout the United States and "strategic partners" around the world.
